[6-K] Addex Therapeutics Ltd American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Addex Therapeutics (ADXN) filed a Form 6-K reporting the incorporation of a press release dated June 25, 2025 into their SEC filings. The press release will be incorporated by reference into two existing registration statements:

• Form F-3 (Registration No. 333-255089)
• Form S-8 (Registration Numbers 333-255124 and 333-272515)

The document was signed by Tim Dyer, Chief Executive Officer. While the filing mentions the press release as Exhibit 99.1, the actual content of the press release is not included in this filing. This is a routine foreign issuer filing that serves primarily to incorporate the referenced press release into the company's existing registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 06/25/2025 - 06:05 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-39179

Addex Therapeutics Ltd
(Translation of registrant's name into English)

Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On June 25, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated June 25, 2025

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Addex Therapeutics Ltd
		(Registrant)
Date: June 25, 2025		/s/ Tim Dyer
		Tim Dyer
		Chief Executive Officer

EXHIBIT INDEX 

Exhibit Number		Description
99.1		Press release dated June 25, 2025